[Neutralizing antibodies against salmon calcitonin. The cause of a treatment failure in Paget's disease].
A 72-year-old woman with Paget's disease of the femur (increasing curvature of the femur in the last 20 years, lately with ever more pain on walking) was at first treated with salmon calcitonin, daily 400 IU nasally, for 2 years. As a result, alkaline phosphatase (AP) concentration fell from initially 703 U/l, to 401 U/l after 7 months' treatment. An increase in AP concentration was first noted after 10 months of treatment, rising after 24 months to 688 U/l. The symptoms, initially having responded rather well to therapy, markedly progressed. In parallel, titres were recorded for binding (maximally 1:100) and neutralizing antibodies (neutralizing action maximally 75%) against salmon calcitonin. Because of the development of secondary resistance to salmon calcitonin the medication was changed to human calcitonin (100 IU daily, subcutaneously). This again resulted in a fall of the AP concentration (to 319 U/l), which remained essentially unchanged (401 U/l) over a period of 17 months on 100 IU human calcitonin three times weekly.
Grauer
A
A
Abteilung für Innere Medizin I, Universität Heidelberg.
Frank-Raue
K
K
Schroth
J
J
Raue
F
F
Ziegler
R
R
D000368:Aged; D000700:Analgesics / Q000276:immunology / Q000627:therapeutic use*; D000906:Antibodies / Q000276:immunology*; D002116:Calcitonin / Q000276:immunology / Q000627:therapeutic use*; D005260:Female; D005269:Femur; D006801:Humans; D009500:Neutralization Tests; D010001:Osteitis Deformans / Q000188:drug therapy* / Q000276:immunology
D000700:Analgesics; D000906:Antibodies; D002116:Calcitonin
Neutralisierende Antikörper gegen Lachscalcitonin. Ursache für ein Therapieversagen bei Morbus Paget.